Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;23(7):731-744.
doi: 10.1080/14737140.2023.2213892. Epub 2023 May 24.

Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review

Kanchi Patell  1 , Matthew Kurian  1 , Jorge A Garcia  1   2 , Prateek Mendiratta  1   2 , Pedro C Barata  1   2 , Angela Y Jia  3   2 , Daniel E Spratt  3   2 , Jason R Brown  1   2
Affiliations

Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review

Kanchi Patell et al. Expert Rev Anticancer Ther. 2023 Jul.

Abstract

Introduction: Metastatic castrate resistant prostate cancer (mCPRC) remains an aggressive form of prostate cancer that no longer responds to traditional hormonal treatment alone. Despite the advent of novel anti-androgen medications, many patients continue to progress, and as a result, there is a growing need for additional treatment options.

Areas covered: Lutetium-177 (177Lu) - PSMA-617 has become one of the new frontline treatment options for refractory metastatic castrate resistant prostate cancer after the failure of novel anti-androgen therapy and chemotherapy. Lu-177 has been used in real-world prospective trials and is now becoming utilized in newer phase III clinical trials. Here, we present a comprehensive overview of the current literature, covering retrospective studies, prospective studies, and clinical trials that established Lutetium-177-PSMA-617 (177Lu-PSMA-617) for the treatment of mCRPC.

Expert opinion: 177Lu - PSMA-617 has been approved for treatment of mCRPC based on positive phase III studies. While this treatment is tolerable and effective, biomarkers are necessary to determine which patients will benefit. In the future, radioligand treatments will likely be utilized in earlier lines of therapy and potentially in combination with other prostate cancer treatments.

Keywords: 177Lu-PSMA-617; Pluvicto; clinical trials; metastatic castrate resistant prostate cancer; prostate cancer; prostate-specific membrane antigen; radioligand therapy.

PubMed Disclaimer

Publication types